Karuna Therapeutics to Present at Upcoming Investor Conferences

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Wednesday, August 28, 2019
Information
Tags: 
Mental health, Health, Clinical trials, Pharmaceutical, Biotechnology, Psychiatry, Articles, Life sciences, Psychopathology, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Karuna, Biopharmaceutical, Psychosis
Geotags: 
United States, Massachusetts
⚠generated by AI ↴
Summary
Key Points: 
  • Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.
  • Location: The Westin Copley Place Hotel, Boston, MA
    Karuna is an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need.
  • Karuna is currently conducting a Phase 2 clinical trial of its lead product candidate, KarXT (Karuna-Xanomeline-Trospium), for the treatment of acute psychosis in patients with schizophrenia.
  • Karuna also plans to initiate clinical trials of KarXT to evaluate its potential therapeutic benefit in other central nervous system disorders, including psychosis in Alzheimers disease, as well as pain.


Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

Wells Fargo Securities 2018 Healthcare Conference

Date: Wednesday, September 4, 2019

Time: 3:35 p.m. ET

Location: The Westin Copley Place Hotel, Boston, MA

Citi’s 14th Annual Biotech Conference

Date: Thursday, September 5, 2019

Location: The Four Seasons Hotel, Boston, MA

About Karuna

Karuna is an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Karuna is currently conducting a Phase 2 clinical trial of its lead product candidate, KarXT (Karuna-Xanomeline-Trospium), for the treatment of acute psychosis in patients with schizophrenia. Karuna also plans to initiate clinical trials of KarXT to evaluate its potential therapeutic benefit in other central nervous system disorders, including psychosis in Alzheimer’s disease, as well as pain.

Copyright: 
Copyright Business Wire 2019